IPO in March 2022 (NASDAQ: ANTX)

AN2 Therapeutics (“AN2”) is a biopharmaceutical company focused on developing novel medicines for patients with rare, orphan infectious diseases that represent significant unmet needs. Founded by a team of experienced industry leaders in infectious diseases drug research and development, we strive to provide patients with treatments that will restore their health and enable them to live productive lives.

AN2 is a mission-driven company. We have a passion for improving global public health and a vision to accelerate development of novel medicines to treat serious infectious diseases and save lives worldwide.